Do analysts prefer SXTC or FBLG?

FibroBiologics has a consensus target price of $74.00, suggesting a potential upside of 6,815.89%. Given FibroBiologics' stronger consensus rating and higher probable upside, analysts plainly believe FibroBiologics is more favorable than China SXT Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China SXT Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 FibroBiologics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings & valuation, SXTC or FBLG?

China SXT Pharmaceuticals has higher revenue and earnings than FibroBiologics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio China SXT Pharmaceuticals $1.74M 0.87 -$3.30M N/A N/A FibroBiologics N/A N/A -$18.65M -$6.93 N/A

Is SXTC or FBLG more profitable?

China SXT Pharmaceuticals' return on equity of 0.00% beat FibroBiologics' return on equity. Company Net Margins Return on Equity Return on Assets China SXT Pharmaceuticals N/A N/A N/A FibroBiologics N/A -767.07% -195.56%

Does the media refer more to SXTC or FBLG?

In the previous week, China SXT Pharmaceuticals and China SXT Pharmaceuticals both had 3 articles in the media. China SXT Pharmaceuticals' average media sentiment score of 0.90 beat FibroBiologics' score of 0.66 indicating that China SXT Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment China SXT Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive FibroBiologics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer INM or SXTC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 China SXT Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, INM or SXTC?

China SXT Pharmaceuticals has lower revenue, but higher earnings than InMed Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InMed Pharmaceuticals $4.94M 1.05 -$8.16M -$2.89 N/A China SXT Pharmaceuticals $1.74M 0.87 -$3.30M N/A N/A

Do analysts recommend APM or SXTC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptorum Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 China SXT Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, APM or SXTC?

Aptorum Group has higher earnings, but lower revenue than China SXT Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aptorum Group $430K 16.10 -$1.36M N/A N/A China SXT Pharmaceuticals $1.74M 0.87 -$3.30M N/A N/A

Is APM or SXTC more profitable?

Company Net Margins Return on Equity Return on Assets Aptorum Group N/A N/A N/A China SXT Pharmaceuticals N/A N/A N/A

Does the media prefer APM or SXTC?

In the previous week, China SXT Pharmaceuticals had 2 more articles in the media than Aptorum Group. MarketBeat recorded 3 mentions for China SXT Pharmaceuticals and 1 mentions for Aptorum Group. Aptorum Group's average media sentiment score of 0.94 beat China SXT Pharmaceuticals' score of 0.90 indicating that Aptorum Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aptorum Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive China SXT Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate CDT or SXTC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 China SXT Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, CDT or SXTC?

China SXT Pharmaceuticals has higher revenue and earnings than CDT Equity. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CDT Equity N/A N/A -$39.22M -$66.34 thousand N/A China SXT Pharmaceuticals $1.74M 0.87 -$3.30M N/A N/A

Is CDT or SXTC more profitable?

China SXT Pharmaceuticals' return on equity of 0.00% beat CDT Equity's return on equity. Company Net Margins Return on Equity Return on Assets CDT Equity N/A -4,263.33% -529.91% China SXT Pharmaceuticals N/A N/A N/A

Does the media prefer CDT or SXTC?

In the previous week, CDT Equity had 1 more articles in the media than China SXT Pharmaceuticals. MarketBeat recorded 4 mentions for CDT Equity and 3 mentions for China SXT Pharmaceuticals. China SXT Pharmaceuticals' average media sentiment score of 0.90 beat CDT Equity's score of 0.29 indicating that China SXT Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CDT Equity 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral China SXT Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate BGMS or SXTC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cyclacel Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 China SXT Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, BGMS or SXTC?

Cyclacel Pharmaceuticals has higher earnings, but lower revenue than China SXT Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cyclacel Pharmaceuticals $750K 7.80 -$3M -$4.54 N/A China SXT Pharmaceuticals $1.74M 0.87 -$3.30M N/A N/A

Is BGMS or SXTC more profitable?

China SXT Pharmaceuticals' return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Cyclacel Pharmaceuticals N/A -51.21% -44.00% China SXT Pharmaceuticals N/A N/A N/A

Does the media prefer BGMS or SXTC?

In the previous week, Cyclacel Pharmaceuticals and Cyclacel Pharmaceuticals both had 3 articles in the media. Cyclacel Pharmaceuticals' average media sentiment score of 0.93 beat China SXT Pharmaceuticals' score of 0.90 indicating that Cyclacel Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cyclacel Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive China SXT Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

China SXT Pharmaceuticals (SXTC) Competitors

$1.57 -0.16 (-9.25%)

Closing price 03:59 PM Eastern

Extended Trading

$1.60 +0.03 (+2.10%)

As of 07:56 PM Eastern

Compare

SXTC vs. FBLG, INM, APM, CDT, and BGMS

Should you buy China SXT Pharmaceuticals stock or one of its competitors? MarketBeat compares China SXT Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with China SXT Pharmaceuticals include FibroBiologics (FBLG), InMed Pharmaceuticals (INM), Aptorum Group (APM), CDT Equity (CDT), and Cyclacel Pharmaceuticals (BGMS). These companies are all part of the "pharmaceutical products" industry.

How does China SXT Pharmaceuticals compare to FibroBiologics?

China SXT Pharmaceuticals (NASDAQ:SXTC) and FibroBiologics (NASDAQ:FBLG) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability.

FibroBiologics has a consensus target price of $74.00, suggesting a potential upside of 6,815.89%. Given FibroBiologics' stronger consensus rating and higher probable upside, analysts plainly believe FibroBiologics is more favorable than China SXT Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China SXT Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
FibroBiologics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

China SXT Pharmaceuticals' return on equity of 0.00% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China SXT Pharmaceuticals	N/A	N/A	N/A
FibroBiologics	N/A	-767.07%	-195.56%

In the previous week, China SXT Pharmaceuticals and China SXT Pharmaceuticals both had 3 articles in the media. China SXT Pharmaceuticals' average media sentiment score of 0.90 beat FibroBiologics' score of 0.66 indicating that China SXT Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
China SXT Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
FibroBiologics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. 4.0% of China SXT Pharmaceuticals shares are owned by insiders. Comparatively, 9.3% of FibroBiologics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

China SXT Pharmaceuticals has higher revenue and earnings than FibroBiologics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China SXT Pharmaceuticals	$1.74M	0.87	-$3.30M	N/A	N/A
FibroBiologics	N/A	N/A	-$18.65M	-$6.93	N/A

China SXT Pharmaceuticals has a beta of 1.91, indicating that its stock price is 91% more volatile than the broader market. Comparatively, FibroBiologics has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market.

Summary

China SXT Pharmaceuticals beats FibroBiologics on 7 of the 11 factors compared between the two stocks.

How does China SXT Pharmaceuticals compare to InMed Pharmaceuticals?

InMed Pharmaceuticals (NASDAQ:INM) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

20.1% of InMed Pharmaceuticals shares are owned by institutional investors. Comparatively, 5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. 0.9% of InMed Pharmaceuticals shares are owned by company insiders. Comparatively, 4.0% of China SXT Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

China SXT Pharmaceuticals has lower revenue, but higher earnings than InMed Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMed Pharmaceuticals	$4.94M	1.05	-$8.16M	-$2.89	N/A
China SXT Pharmaceuticals	$1.74M	0.87	-$3.30M	N/A	N/A

InMed Pharmaceuticals has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market. Comparatively, China SXT Pharmaceuticals has a beta of 1.91, meaning that its stock price is 91% more volatile than the broader market.

China SXT Pharmaceuticals has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -132.87%. China SXT Pharmaceuticals' return on equity of 0.00% beat InMed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%
China SXT Pharmaceuticals	N/A	N/A	N/A

In the previous week, China SXT Pharmaceuticals had 3 more articles in the media than InMed Pharmaceuticals. MarketBeat recorded 3 mentions for China SXT Pharmaceuticals and 0 mentions for InMed Pharmaceuticals. InMed Pharmaceuticals' average media sentiment score of 1.89 beat China SXT Pharmaceuticals' score of 0.90 indicating that InMed Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
InMed Pharmaceuticals	Very Positive
China SXT Pharmaceuticals	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
China SXT Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

China SXT Pharmaceuticals beats InMed Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does China SXT Pharmaceuticals compare to Aptorum Group?

Aptorum Group (NASDAQ:APM) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

3.8% of Aptorum Group shares are held by institutional investors. Comparatively, 5.0% of China SXT Pharmaceuticals shares are held by institutional investors. 64.0% of Aptorum Group shares are held by insiders. Comparatively, 4.0% of China SXT Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Aptorum Group has higher earnings, but lower revenue than China SXT Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptorum Group	$430K	16.10	-$1.36M	N/A	N/A
China SXT Pharmaceuticals	$1.74M	0.87	-$3.30M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptorum Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
China SXT Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, China SXT Pharmaceuticals had 2 more articles in the media than Aptorum Group. MarketBeat recorded 3 mentions for China SXT Pharmaceuticals and 1 mentions for Aptorum Group. Aptorum Group's average media sentiment score of 0.94 beat China SXT Pharmaceuticals' score of 0.90 indicating that Aptorum Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aptorum Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
China SXT Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
Aptorum Group	N/A	N/A	N/A
China SXT Pharmaceuticals	N/A	N/A	N/A

Aptorum Group has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market. Comparatively, China SXT Pharmaceuticals has a beta of 1.91, indicating that its share price is 91% more volatile than the broader market.

Summary

Aptorum Group and China SXT Pharmaceuticals tied by winning 4 of the 8 factors compared between the two stocks.

How does China SXT Pharmaceuticals compare to CDT Equity?

CDT Equity (NASDAQ:CDT) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

China SXT Pharmaceuticals' return on equity of 0.00% beat CDT Equity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CDT Equity	N/A	-4,263.33%	-529.91%
China SXT Pharmaceuticals	N/A	N/A	N/A

CDT Equity has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market. Comparatively, China SXT Pharmaceuticals has a beta of 1.91, suggesting that its share price is 91% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
China SXT Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

China SXT Pharmaceuticals has higher revenue and earnings than CDT Equity.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CDT Equity	N/A	N/A	-$39.22M	-$66.34 thousand	N/A
China SXT Pharmaceuticals	$1.74M	0.87	-$3.30M	N/A	N/A

3.3% of CDT Equity shares are held by institutional investors. Comparatively, 5.0% of China SXT Pharmaceuticals shares are held by institutional investors. 10.8% of CDT Equity shares are held by company insiders. Comparatively, 4.0% of China SXT Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, CDT Equity had 1 more articles in the media than China SXT Pharmaceuticals. MarketBeat recorded 4 mentions for CDT Equity and 3 mentions for China SXT Pharmaceuticals. China SXT Pharmaceuticals' average media sentiment score of 0.90 beat CDT Equity's score of 0.29 indicating that China SXT Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CDT Equity	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
China SXT Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

China SXT Pharmaceuticals beats CDT Equity on 7 of the 9 factors compared between the two stocks.

How does China SXT Pharmaceuticals compare to Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals (NASDAQ:BGMS) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends.

In the previous week, Cyclacel Pharmaceuticals and Cyclacel Pharmaceuticals both had 3 articles in the media. Cyclacel Pharmaceuticals' average media sentiment score of 0.93 beat China SXT Pharmaceuticals' score of 0.90 indicating that Cyclacel Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cyclacel Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
China SXT Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cyclacel Pharmaceuticals has higher earnings, but lower revenue than China SXT Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclacel Pharmaceuticals	$750K	7.80	-$3M	-$4.54	N/A
China SXT Pharmaceuticals	$1.74M	0.87	-$3.30M	N/A	N/A

China SXT Pharmaceuticals' return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cyclacel Pharmaceuticals	N/A	-51.21%	-44.00%
China SXT Pharmaceuticals	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclacel Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
China SXT Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cyclacel Pharmaceuticals has a beta of -0.4, suggesting that its stock price is 140% less volatile than the broader market. Comparatively, China SXT Pharmaceuticals has a beta of 1.91, suggesting that its stock price is 91% more volatile than the broader market.

23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. Comparatively, 5.0% of China SXT Pharmaceuticals shares are held by institutional investors. 23.8% of Cyclacel Pharmaceuticals shares are held by insiders. Comparatively, 4.0% of China SXT Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Cyclacel Pharmaceuticals beats China SXT Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Get China SXT Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SXTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SXTC vs. The Competition

Export

Metric	China SXT Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.67M	$2.97B	$6.44B	$12.46B
Dividend Yield	N/A	1.68%	2.69%	5.22%
P/E Ratio	N/A	18.12	23.87	24.36
Price / Sales	0.87	303.59	521.52	117.01
Price / Cash	N/A	55.72	41.27	57.13
Price / Book	0.00	3.95	9.99	6.73
Net Income	-$3.30M	$75.85M	$3.56B	$337.03M
7 Day Performance	0.64%	-1.13%	-0.89%	0.09%
1 Month Performance	N/A	N/A	N/A	-1.78%
1 Year Performance	-99.20%	23.03%	28.76%	33.98%

China SXT Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SXTC China SXT Pharmaceuticals	0.465 of 5 stars	$1.57 -9.2%	N/A	-99.1%	$1.67M	$1.74M	N/A	90	Short Interest Increase Gap Down
FBLG FibroBiologics	3.4831 of 5 stars	$1.12 +5.7%	$74.00 +6,507.1%	-93.2%	$5.84M	N/A	N/A	10	News Coverage Analyst Downgrade Short Interest Increase
INM InMed Pharmaceuticals	2.0118 of 5 stars	$1.66 -3.5%	N/A	-52.6%	$5.50M	$4.94M	N/A	10	Gap Down
APM Aptorum Group	1.3752 of 5 stars	$0.85 +0.7%	N/A	+5.3%	$5.40M	N/A	N/A	30	Gap Down
CDT CDT Equity	0.2838 of 5 stars	$1.10 +24.4%	N/A	-99.9%	$5.35M	N/A	N/A	3	Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SXTC) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

China SXT Pharmaceuticals (SXTC) Competitors

SXTC vs. FBLG, INM, APM, CDT, and BGMS

How does China SXT Pharmaceuticals compare to FibroBiologics?

Summary

How does China SXT Pharmaceuticals compare to InMed Pharmaceuticals?

Summary

How does China SXT Pharmaceuticals compare to Aptorum Group?

Summary

How does China SXT Pharmaceuticals compare to CDT Equity?

Summary

How does China SXT Pharmaceuticals compare to Cyclacel Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTC vs. The Competition

China SXT Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

China SXT Pharmaceuticals (SXTC) Competitors

SXTC vs. FBLG, INM, APM, CDT, and BGMS

How does China SXT Pharmaceuticals compare to FibroBiologics?

Do analysts prefer SXTC or FBLG?

Is SXTC or FBLG more profitable?

Does the media refer more to SXTC or FBLG?

Do institutionals and insiders have more ownership in SXTC or FBLG?

Which has stronger earnings & valuation, SXTC or FBLG?

Which has more risk & volatility, SXTC or FBLG?

Summary

How does China SXT Pharmaceuticals compare to InMed Pharmaceuticals?

Do institutionals & insiders have more ownership in INM or SXTC?

Which has stronger earnings & valuation, INM or SXTC?

Which has more volatility & risk, INM or SXTC?

Is INM or SXTC more profitable?

Does the media favor INM or SXTC?

Do analysts prefer INM or SXTC?

Summary

How does China SXT Pharmaceuticals compare to Aptorum Group?

Do insiders and institutionals hold more shares of APM or SXTC?

Which has better valuation & earnings, APM or SXTC?

Do analysts recommend APM or SXTC?

Does the media prefer APM or SXTC?

Is APM or SXTC more profitable?

Which has more volatility & risk, APM or SXTC?

Summary

How does China SXT Pharmaceuticals compare to CDT Equity?

Is CDT or SXTC more profitable?

Which has more volatility and risk, CDT or SXTC?

Do analysts rate CDT or SXTC?

Which has preferable earnings & valuation, CDT or SXTC?

Do insiders and institutionals believe in CDT or SXTC?

Does the media prefer CDT or SXTC?

Summary

How does China SXT Pharmaceuticals compare to Cyclacel Pharmaceuticals?

Does the media prefer BGMS or SXTC?

Which has stronger valuation & earnings, BGMS or SXTC?

Is BGMS or SXTC more profitable?

Do analysts rate BGMS or SXTC?

Which has more risk & volatility, BGMS or SXTC?

Do institutionals & insiders believe in BGMS or SXTC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTC vs. The Competition

China SXT Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools